Franz Payer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Franz Payer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Etienne Holl
Department of Neurosurgery, Medical University of Graz, Austria
1 shared publication - Franz Fazekas
Department of Neurology, Medical University of Graz, Graz, Austria
1 shared publication - Johannes Haybaeck
Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
1 shared publication - Martin Asslaber
Institute of Pathology, Medical University of Graz, Graz, Austria
1 shared publication - Tadeja Urbanic Purkart
Universitätsklinik für Neurologie, Medizinische Universität Graz, Graz, Österreich
1 shared publication - Thomas Seifert-Held
Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria
1 shared publication
Latest Publications
- 1 September 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 404, 40-43
Vanishing midbrain mass lesion - A germinoma?
- 1 September 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 404, 40-43
Vanishing midbrain mass lesion - A germinoma?
- 1 January 2011
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 161 (1) , 13-19
Pseudoprogression oder Pseudorespons: Herausforderung an die Bildgebung des Glioblastoma multiforme
Summary This methodological paper on magnetic resonance tomography imaging recalls the assessment criteria on therapy response of Glioblastoma multiforme as defined by David Macdonald in 1990 that have remained State of the Art since their first publication. It defines the terms "pseudoprogression", "radiation induced necrosis" and "pseudoresponse". These phenomena are seen increasingly since the introduction of radiochemotherapy with Temozolomide as treatment standard in glioblastoma and since the use of antiangiogenetic therapy in malignant gliomas. Therefore, the assessment criteria have been recently updated with the newly proposed "RANO criteria (Response assessment in Neuro-Oncology)". Furthermore, the potential of additional information to conventional MR by MR perfusion, MR diffusion and MR spectroscopy is briefly discussed.
- 1 January 2011
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 161 (1) , 13-19
Pseudoprogression oder Pseudorespons: Herausforderung an die Bildgebung des Glioblastoma multiforme
Summary This methodological paper on magnetic resonance tomography imaging recalls the assessment criteria on therapy response of Glioblastoma multiforme as defined by David Macdonald in 1990 that have remained State of the Art since their first publication. It defines the terms "pseudoprogression", "radiation induced necrosis" and "pseudoresponse". These phenomena are seen increasingly since the introduction of radiochemotherapy with Temozolomide as treatment standard in glioblastoma and since the use of antiangiogenetic therapy in malignant gliomas. Therefore, the assessment criteria have been recently updated with the newly proposed "RANO criteria (Response assessment in Neuro-Oncology)". Furthermore, the potential of additional information to conventional MR by MR perfusion, MR diffusion and MR spectroscopy is briefly discussed.